TITLE

America's Other Drug Problem

AUTHOR(S)
Relman, Arnold S.; Angell, Marcia
PUB. DATE
December 2002
SOURCE
New Republic;12/16/2002, Vol. 227 Issue 25, p27
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses several problems concerning the U.S. pharmaceutical industry as of December 2002. Information on the increased cost of drugs; Costs of drug research and development; Innovations contributed by the industry to medicine; Issues regarding the clinical trials of drugs; Information on drug marketing.
ACCESSION #
8631358

 

Related Articles

  • Increased R&D Investments by Big Pharma Expected to Lift the Global Clinical Trials Market.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p183 

    The article reports on the shift of the global clinical trials market towards conducting trials from developed world to the emerging economies. It is revealed that factors driving growth in clinical trial market include the trend for globalization of drug research and development and cost...

  • Robust CRO Market New Merger and Acqusition Activity. Miller, Jim // Pharmaceutical Technology;Dec2004, Vol. 28 Issue 12, p72 

    This article reports that public contract research organizations reported strong quarterly results for the period that ended September 30, 2004. Overall, pharmaceutical industry revenues were up nearly 9%, but several smaller companies experienced more than 50% top line growth. The big gains...

  • TRANSPARENCY AND INNUENDO: AN ALTERNATIVE TO REACTIVE OVERDISCLOSURE. Lassman, Scott M. // Law & Contemporary Problems;Summer2006, Vol. 69 Issue 3, p69 

    The article reports on the call for increased transparency on safety issues concerning pharmaceutical research and safety information on drug products. It offers an overview of the pharmaceutical industry's commitment to the transparency through timely communication of controlled clinical trial...

  • CRO Use on the Rise.  // Pharmaceutical Executive;Mar2006, Vol. 26 Issue 3, p36 

    The article focuses on the significance of contract research organizations in drug development. In addition, the number of clinical trials conducted by such organizations increased. Moreover, these organizations tend to be utilized for larger development projects, with a large number of...

  • Drug Trials: It's All in the Data.  // Drug Discovery & Development;Nov2010, Vol. 13 Issue 9, p34 

    The article focuses on the effect of clinical trials towards the progress of drug candidates in the pharmaceutical research and development. It mentions the factors influencing the success of clinical trials together with the deployment of the right technology including the data collection,...

  • Calendar of Events.  // Applied Clinical Trials;Aug2005, Vol. 14 Issue 8, p64 

    Presents calendar of events related to clinical trial. Schedule of the Advanced Topics in Clinical Research/Drug Development Training Course; Web site address for the Outsourcing Foundation Course; Venue of the Clinical Development Program Planning and Trial Design.

  • The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences: Part 2. A Qualitative, Systematic Review of the Literature on Possible Influences on Authorship, Access to Trial Data, and Trial Registration and Publication. Schott, Gisela; Pachl, Henry; Limbach, Ulrich; Gundert-Remy, Ursula; Lieb, Klaus; Ludwig, Wolf-Dieter // Deutsches Aerzteblatt International;4/30/2010, Vol. 107 Issue 17, p1 

    The article reports on the results of the research on the challenges and possible influences on authorship of clinical drug trials financed by pharmaceutical companies in the U.S. Researchers found that despite the benefits of these experiments to pharmaceutical firms, trial results can be...

  • Early access programs: Benefits, challenges, and key considerations for successful implementation. Patil, Sanjaykumar // Perspectives in Clinical Research;Jan-Mar2016, Vol. 7 Issue 1, p4 

    Early access programs, (EAPs) are adopted by an increasing number of pharma companies due to several benefits offered by these programs. EAPs offer ethical, compliant, and controlled mechanisms of access to investigational drugs outside of the clinical trial space and before the commercial...

  • Bacterial (Pyogenic) Meningitis - Pipeline Review, H1 2012.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that Research & Markets Ltd. has announced the inclusion of the company Global Markets Direct's new report "Bacterial(Pyogenic) Meningitis - Pipeline Review, H1 2012" to their offering. The report provides information on the therapeutic development for bacterial meningitis...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics